Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | PDE5A | O76074 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CCND1 | P24385 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CCND3 | P30281 | 3/20 | 0.47 |
| ▸ | CDK7 | P50613 | 3/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.47 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633395 | 0.82 | CDK2 (0.49) | CDK4CDK6CCNT1CDK1CCNA2 | |
| SCHEMBL1633850 | 0.82 | JAK2 (0.65) | SRCCA12CA2CDK4CDK6 | |
| SCHEMBL1632814 | 0.81 | CDK2 (0.52) | CA12CA2CDK4CCNT1CDK1 | |
| SCHEMBL1631342 | 0.81 | CDK2 (0.45) | CDK4CCNT1CDK1CCNA2CCND1 | |
| SCHEMBL1632354 | 0.77 | PKM (0.43) | CDK4CCNT1CDK1CCND1CCNE1 | |
| SCHEMBL1633421 | 0.75 | MAP3K5 (0.49) | SRCCDK4CDK1CCND1CCNE1 | |
| SCHEMBL1633858 | 0.75 | JAK2 (0.49) | CDK4CCNT1CDK1CCNA2CCND1 | |
| SCHEMBL1634323 | 0.74 | JAK2 (0.47) | CDK4CDK1CCND1CCNE1CDK2 | |
| SCHEMBL26061435 | 0.74 | ALK (0.64) | BRD4CDK4CDK1CCND1CCNE1 | |
| SCHEMBL1634282 | 0.74 | ACVR1 (0.52) | CCNT1CDK1CCNA2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRD4 268/4885PDE5A 1233/4885SRC 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.